We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-6.2%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.77B
AUM Growth
-$356M
(-7%)
Cap. Flow
-$1.35B
Cap. Flow
% of AUM
-28.26%
Top 10 Holdings %
Top 10 Hldgs %
39.93%
Holding
155
New
23
Increased
16
Reduced
21
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$89.6M |
| 2 |
AdaptHealth
AHCO
|
+$49.8M |
| 3 |
ESPR
Esperion Therapeutics
ESPR
|
+$40M |
| 4 |
Xilio Therapeutics
XLO
|
+$36.7M |
| 5 |
FIGS
FIGS
|
+$27.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BDSI
BioDelivery Sciences International, Inc.
BDSI
|
+$30.8M |
| 2 |
Molina Healthcare
MOH
|
+$28.8M |
| 3 |
Cytokinetics
CYTK
|
+$28.1M |
| 4 |
XLRN
Acceleron Pharma
XLRN
|
+$25M |
| 5 |
Fate Therapeutics
FATE
|
+$21.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 62.96% |
| 2 | Financials | 1.4% |
| 3 | Consumer Discretionary | 0.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NUVL
1
DELISTED
Nuvalent
NUVL
| $368M | 7.72% |
19,341,024
| – | – |
|
2
Viatris
VTRS
$20.1B
| $281M | 5.9% |
20,774,000
+1,950,000
| +10% | +$26M |
|
|
3
AdaptHealth
AHCO
$1.49B
| $250M | 5.25% |
10,225,445
+2,121,653
| +26% | +$49.8M |
|
|
CMAX
4
DELISTED
CareMax, Inc. Class A Common Stock
CMAX
| $129M | 2.7% |
559,292
| – | – |
|
5
Neurocrine Biosciences
NBIX
$17.2B
| $117M | 2.46% |
1,377,945
+235,530
| +21% | +$21.7M |
|
|
OMIC
6
DELISTED
Singular Genomics Systems, Inc. Common Stock
OMIC
| $105M | 2.21% |
303,734
| – | – |
|
7
Centene
CNC
$32.8B
| $82.7M | 1.73% |
1,003,800
| – | – |
|
|
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $79.6M | 1.67% |
4,761,138
-102,587
| -2% | -$1.68M |
|
9
Organogenesis Holdings
ORGO
$337M
| $78.1M | 1.64% |
8,456,876
+994,333
| +13% | +$10.6M |
|
10
Pulmonx
LUNG
$59.1M
| $75.9M | 1.59% |
2,366,867
+336,980
| +17% | +$12.3M |
|
|
SILK
11
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $64.6M | 1.36% |
1,517,181
+526,930
| +53% | +$26.4M |
|
12
Larimar Therapeutics
LRMR
$384M
| $62.9M | 1.32% |
5,830,249
| – | – |
|
13
GeneDx Holdings
WGS
$1.88B
| $62.3M | 1.31% |
423,237
+3,586
| +0.9% | +$801K |
|
14
Edgewise Therapeutics
EWTX
$4.28B
| $60.1M | 1.26% |
3,933,137
| – | – |
|
|
DCPH
15
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $54.5M | 1.14% |
5,580,456
+4,765,456
| +585% | +$89.6M |
|
|
APR
16
DELISTED
Apria, Inc. Common Stock
APR
| $54M | 1.13% |
1,655,795
+238,095
| +17% | +$7.72M |
|
17
Mirum Pharmaceuticals
MIRM
$7.25B
| $52.4M | 1.1% |
3,282,912
| – | – |
|
18
Glaukos
GKOS
$9.21B
| $51.6M | 1.08% |
1,161,414
+542,414
| +88% | +$25M |
|
19
Kura Oncology
KURA
$964M
| $49.2M | 1.03% |
3,513,756
+1,198,339
| +52% | +$19.4M |
|
|
20
Molina Healthcare
MOH
$11.7B
| $42.9M | 0.9% |
134,989
-96,787
| -42% | -$28.8M |
|
21
Alphatec Holdings
ATEC
$1.31B
| $41.1M | 0.86% |
3,594,829
| – | – |
|
22
Protagonist Therapeutics
PTGX
$9.06B
| $40.1M | 0.84% |
1,172,943
-221,057
| -16% | -$6.99M |
|
|
DAWN
23
DELISTED
Day One Biopharmaceuticals
DAWN
| $37.1M | 0.78% |
2,202,533
+491,803
| +29% | +$10.1M |
|
|
24
Cytokinetics
CYTK
$10.9B
| $36.9M | 0.77% |
809,000
-727,758
| -47% | -$28.1M |
|
25
Pacira BioSciences
PCRX
$1.01B
| $35.9M | 0.75% |
596,338
-370,898
| -38% | -$20.5M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q4 2021 Portfolio in Review
As of Q4 2021, Deerfield Management held 155 positions worth $4.77B, down 7% from $5.12B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Deerfield Management withdrew a net $1.35B in Q4 2021, closing 28 positions and reducing 21 holdings. Its most notable exit was Acceleron Pharma, an estimated $25M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 66% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Deerfield Management opened a new position in Esperion Therapeutics worth $25M.
- Deerfield Management's largest Q4 2021 buy was Esperion Therapeutics: 5,000,000 shares worth $25M.
- Deerfield Management added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2021, an estimated $89.6M increase.
- Deerfield Management's biggest Q4 2021 reduction was BioDelivery Sciences International, Inc., cutting an estimated $30.8M.
- Deerfield Management fully exited Acceleron Pharma in Q4 2021, selling an estimated $25M.
- Deerfield Management's ten largest holdings make up 40% of its $4.77B portfolio in Q4 2021.
- Deerfield Management opened 23 new positions and closed 28 in Q4 2021.
- Deerfield Management's portfolio value fell 7% quarter-over-quarter to $4.77B.
Based on Deerfield Management's 13F filing for Q4 2021, filed 14 Feb 2022.